Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

New report on the immunomodulators market outlook to 2016

TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, according to a new report available on companiesandmarkets.com. The top three products: Remicade, Humira and Enbrel accounted for 40.1% of the market in 2010.

23 Aug 2011

Scientists discover key defense mechanism against C. difficile infection

Researchers have discovered a key mechanism used by intestinal cells to defend themselves against one of the world's most common hospital-acquired bacterial infections - a mechanism they think they can exploit to produce a therapy to protect against the effects of the antibiotic-resistant bacteria.

22 Aug 2011

New CDI therapeutic approach may offer treatment for other bacterial diseases

Researchers at the David Geffen School of Medicine at UCLA and the University of Texas Medical Branch at Galveston have discovered a molecular process by which the body can defend against the effects of Clostridium difficile infection (CDI), pointing the way to a promising new approach for treating an intestinal disease that has become more common, more severe and harder to cure in recent years.

22 Aug 2011

Scientists turn drug-disease match makers

In a new medical breakthrough American researchers have devised a drug-disease matchmaking program that mines databases for potentially useful new treatment combinations and have actually turned up two so far, said a study on Wednesday.

18 Aug 2011

New tool can identify patients at high risk of venous thromboembolism

A new risk prediction tool can identify patients at high risk of serious blood clots (known as venous thromboembolism) who might need preventative treatment, says a study published on bmj.com today.

17 Aug 2011

Study finds large variation in reoperation rates after colorectal surgery in England

There is a large variation in unplanned reoperation rates after colorectal surgery in English NHS hospitals, finds a study published on bmj.com today.

17 Aug 2011

New insights into causes of rheumatoid arthritis

Scientists at Mount Sinai Hospital, in collaboration with researchers at the University of Toronto, University Health Network and McGill University have obtained significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease.

16 Aug 2011

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Stephanie Nicole "Nikki" Lewis, a graduate student in the interdisciplinary doctoral program in genetics, bioinformatics, and computational biology at Virginia Tech, has been awarded the prestigious Ruth L. Kirschstein National Research Service Award for Predoctoral Research through the National Institutes of Health for her study of a cellular signaling receptor that is associated with chronic inflammatory diseases such as diabetes, obesity, and inflammatory bowel disease.

5 Aug 2011

Avaxia receives BARDA contract to develop new radiation mitigation drug

Avaxia Biologics, Inc., a privately-held biotech company developing oral antibody drugs that act locally within the gastrointestinal tract, announced today it was awarded a contract with the Biomedical Advanced Research and Development Authority (BARDA), for the research and development of an oral antibody therapy to mitigate the gastrointestinal damage that follows radiation exposure that might occur after a nuclear incident.

4 Aug 2011

Researchers sample hydrogenotrophic microbes in the healthy human colon

They make up less than one-hundredth of 1 percent of the microbes that live in the colon, but the bacteria and archaea that sop up hydrogen in the gut are fundamental to colon health. In a new study, researchers take a first look at these "hydrogenotrophic" microbes, mapping where they live and how abundant they are in different parts of the lower intestine.

3 Aug 2011

BARDA awards contracts for development of drugs for radiation injury to the GI tract

The first two contracts for advanced development of drugs to treat gastrointestinal (GI) tract injuries associated with acute radiation syndrome were awarded today by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

2 Aug 2011

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S. This population-based study publishing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, found that metabolic syndrome significantly increases risk of developing these primary liver cancers.

22 Jul 2011

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Janssen Biotech, Inc., formerly Centocor Ortho Biotech Inc., announced today that the Gastrointestinal Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of REMICADE for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

22 Jul 2011

Metabolic syndrome linked to increased risk of primary liver cancers

22 Jul 2011

U.S.News ranks Rush University Medical Center among America's Best Hospitals for 2011-12

Rush University Medical Center has once again been named one of the nation's top hospitals in the nation, according to the upcoming issue of U.S.News & World Report.

21 Jul 2011

Big news for ankylosing spondylitis sufferers

In a medical breakthrough, researchers from the University of Queensland have found that there is a possible genetic link in a specific painful form of arthritis, which fuses bones in the spine and pelvis.

12 Jul 2011

New genetic research on Ankylosing Spondylitis

The team of researchers from the Universities of Bristol, Queensland, Oxford, Texas and Toronto, used a technique called genome-wide association where millions of genetic markers are measured in thousands of people that have the disease and thousands of healthy individuals.

11 Jul 2011

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

BioLineRx, a biopharmaceutical development company, announced today the enrollment of the first patient in the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment of schizophrenia.

28 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Lipid Therapeutics, a biotechnology company focused on novel treatments for inflammatory bowel disease, today announced positive topline results from a Phase IIb clinical trial with its lead product, LT-02, in patients with ulcerative colitis.

22 Jun 2011

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

New report on the immunomodulators market outlook to 2016

Scientists discover key defense mechanism against C. difficile infection

New CDI therapeutic approach may offer treatment for other bacterial diseases

Scientists turn drug-disease match makers

New tool can identify patients at high risk of venous thromboembolism

Study finds large variation in reoperation rates after colorectal surgery in England

New insights into causes of rheumatoid arthritis

Virginia Tech student receives prestigious award for cellular signaling receptor study linked to diabetes, obesity

Avaxia receives BARDA contract to develop new radiation mitigation drug

Researchers sample hydrogenotrophic microbes in the healthy human colon

BARDA awards contracts for development of drugs for radiation injury to the GI tract

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

GIDAC recommends FDA approval of Janssen's REMICADE for treatment of pediatric UC

Metabolic syndrome linked to increased risk of primary liver cancers

U.S.News ranks Rush University Medical Center among America's Best Hospitals for 2011-12

Big news for ankylosing spondylitis sufferers

New genetic research on Ankylosing Spondylitis

BioLineRx initiates enrollment in BL-1020 Phase II/III trial against schizophrenia

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

Positive topline results from Lipid Therapeutics LT-02 Phase IIb trial on ulcerative colitis

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in